According to the FAM molecular subtypes, we have identified 6 FAMRGs (ACLS5, PLA2G2D, PROCA1, IL4I1, UBE2L6) that could significantly contribute to the response of HNSCC patients undergoing anti‐PD1 therapy. Here, PLA2G2D is linked to head and neck squamous cell carcinoma.